Asia Tech Wire (Oct 8) -- Rivus Pharmaceuticals Inc, a U.S. drug developer focused on obesity treatments, may raise more than $250 million through an IPO, according to Bloomberg.

Rivus is in talks with banks about going public and is considering a U.S. IPO as soon as this year, a report on Monday said, citing people familiar with the matter.

Rivus could aim to raise more than $250 million, one of the people familiar with the matter said.

Founded in 2019, Rivus announced in September 2022 that it had closed a $132 million Series B funding round led by RA Capital Management.